Floatz logo

Pitolisant

Narcolepsy-Cataplexy Syndrome

BioprojetSmall moleculePhase 3Dormant
BB
68/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
54/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Narcolepsy-Cataplexy Syndrome cohort.

Asset / SponsorPhaseRating
Modafinil
Bioprojet
Phase 3BB

Same molecule, other indications

Pitolisant is also rated in:

narcolepsyDormant
BB
Indicative · Phase 3
68 / 100
View asset →
Parkinson diseaseDormant
BB
Indicative · Phase 3
65 / 100
View asset →
Prader-Willi syndromeActive
BB
Indicative · Phase 3
64 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →